Orbimed Advisors LLC Arvinas, Inc. Transaction History

Orbimed Advisors LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 16, 2020	SELL	$22.99 - $36.34 $675,906 - $1.07 Million	-29,400 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$29.88 - $56.74 $28.9 Million - $54.8 Million	-965,600 Reduced 97.05%	29,400 $986,000
Q1 2020 May 15, 2020	SELL	$33.0 - $54.5 $29.8 Million - $49.3 Million	-903,800 Reduced 47.6%	995,000 $40.1 Million
Q4 2019 Feb 14, 2020	SELL	$15.39 - $44.38 $3.02 Million - $8.72 Million	-196,483 Reduced 9.38%	1,898,800 $78 Million
Q3 2019 Nov 14, 2019	SELL	$21.55 - $27.61 $12.6 Million - $16.1 Million	-583,527 Reduced 21.78%	2,095,283 $45.2 Million
Q4 2018 Feb 14, 2019	BUY	$11.19 - $18.56 $368,654 - $611,459	32,945 Added 1.25%	2,678,810 $34.4 Million
Q3 2018 Nov 14, 2018	BUY	$16.05 - $16.87 $42.5 Million - $44.6 Million	2,645,865 New	2,645,865 $44.6 Million

224

70.9M

1.52M

346K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $986M
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Orbimed Advisors LLC with notifications on news.